Shilpa Medicare surges on getting USFDA’s approval for Imatinib Mesylate Tablets

18 Jan 2019 Evaluate

Shilpa Medicare is currently trading at Rs. 404.15, up by 9.05 points or 2.29% from its previous closing of Rs. 395.10 on the BSE.

The scrip opened at Rs. 397.75 and has touched a high and low of Rs. 409.90 and Rs. 397.75 respectively. So far 583 shares were traded on the counter.

The BSE group 'B' stock of face value Rs. 1 has touched a 52 week high of Rs. 605.00 on 23-Jan-2018 and a 52 week low of Rs. 357.95 on 23-Jul-2018.

Last one week high and low of the scrip stood at Rs. 398.70 and Rs. 381.05 respectively. The current market cap of the company is Rs. 3242.73 crore.

The promoters holding in the company stood at 53.80%, while Institutions and Non-Institutions held 32.16% and 14.04% respectively.

Shilpa Medicare has received the US Food and Drug Administration (USFDA) approval for its ANDA, Imatinib Mesylate Tablets, 100 mg and 400 mg on January 17, 2019.

Imatinib Mesylate Tablets is a generic equivalent of the reference listed drug (RLD), gleevec Tablets, 100 mg and 400 mg used in the treatment of leukemia as recommended in the label approved by FDA.

According to IQVIA MAT Q2 2018 data, the US market for Imatinib Mesylate Tablets, 100 mg and 400 mg is approximately $885 million.

Shilpa Medicare produces and exports consistently high-quality Active Pharmaceutical Ingredients Fine Chemicals, intermediates, herbal products and speciality chemical products using sophisticated technology, meticulously following international specifications.

Shilpa Medicare Share Price

331.30 -2.65 (-0.79%)
05-Dec-2025 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1804.95
Dr. Reddys Lab 1275.05
Cipla 1520.55
Zydus Lifesciences 931.45
Lupin 2097.65
View more..
Register Now to get our Free Newsletter & much more!

© 2025 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.

×